Trials / Completed
CompletedNCT01636882
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total (VLA-008 CALM Ext)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Viralytics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment. In order to accommodate those patients further treatment to complete 48 weeks of CVA21 intratumoral injections will be made available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CVA21 |
Timeline
- Start date
- 2012-07-03
- Primary completion
- 2016-04-06
- Completion
- 2016-04-06
- First posted
- 2012-07-10
- Last updated
- 2019-07-09
- Results posted
- 2018-04-23
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01636882. Inclusion in this directory is not an endorsement.